Overview

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Status:
Completed
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sirtsei Pharmaceuticals, Inc.